1. Pink Sheet
  2. >>R&D

War on C Difficile Is Being Fought On Multiple Fronts

 
• By Bridget Silverman

Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.

Clostridium difficile bacteria isolated on black background, 3D illustration. Bacteria which cause pseudomembraneous colitis and are associated with nosocomial antibiotic resistance - Illustration

While the fight against antimicrobial resistance often produces more lamentation than new products, some long-stalled therapies for the notoriously challenging bacteria Clostridium difficile have recently shown new signs of life.

Funding from the US government, through the Biomedical Advanced R&D Agency (BARDA), helped Summit Therapeutics PLC start its Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Advocates Want New Bipartisan PBM Reform Package To Stand Alone

 
• By Leslie Small

A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By Vibha Sharma

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By Vibha Sharma

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.